Loading...
OptimizeRx delivered top-line growth and improved bottom-line performance in Q1 2025, supported by enhanced gross profit and positive non-GAAP earnings, alongside raised full-year guidance.
Revenue rose to $21,928,000 from $19,690,000 year-over-year
GAAP net loss narrowed to $2,199,000 from $6,899,000
Non-GAAP net income reached $1,539,000 compared to a loss in Q1 2024
Cash and short-term investments increased to $16,573,000
OptimizeRx increased its FY2025 revenue and adjusted EBITDA guidance following a solid Q1 marked by strong momentum and strategic shifts.